Format

Send to

Choose Destination
Anal Biochem. 2013 Sep 1;440(1):56-62. doi: 10.1016/j.ab.2013.04.031. Epub 2013 May 25.

Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics.

Author information

1
Department of Neurology, Knight Alzheimer's Disease Research Center, Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.

Abstract

Abundant evidence suggests a central role for the amyloid-beta (Aβ) peptide in Alzheimer's disease (AD) pathogenesis. Production and clearance of different Aβ isoforms have been established as targets of proposed disease-modifying therapeutic treatments of AD. However, previous studies used multiple sequential purification steps to isolate the isoforms individually and quantitate them based on a common mid-domain peptide. We created a method to simultaneously purify Aβ isoforms and quantitate them by the specific C-terminal peptides in order to investigate Aβ isoform physiology in the central nervous system. By using standards generated from in vitro metabolic labeling, the relative quantitation of four peptides representing total amount of Aβ (Aβ-Total), Aβ38, Aβ40, and Aβ42 were achieved both in cell culture and in human cerebrospinal fluid (CSF). Standard curves for each isoform demonstrated good sensitivity with very low limits of detection and high accuracy. Because the assay does not require antibody development for each Aβ isoform peptide, significant improvements in the throughput and accuracy of isoform quantitation were achieved.

KEYWORDS:

Alzheimer’s disease; Amyloid-beta isoforms; Cerebrospinal fluid; Mass spectrometry; Relative quantitation

PMID:
23714261
PMCID:
PMC3749773
DOI:
10.1016/j.ab.2013.04.031
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center